Concerns have been raised about the relative effectiveness of an increasing number of new medicines at the time of their market authorisation, a spokesperson for outgoing Dutch Medical Care Minister Pia Dijkstra told Euractiv.
The spokesperson was responding to questions about a letter Dijkstra sent to the Dutch House of Representatives in April in which she outlined her plans to reform the system for the reimbursement of new high-cost medicines.
The minister said patients, doctors, and health insurers have questions about the value of new medicines while facing increasing pharmaceutical expenditure.
“The phased assessment still needs…
